Study of a new drug for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, BMS-986527, for people with advanced kidney cancer that has not responded to standard treatments. The goal is to see if it is safe and if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney cancer called clear cell renal cell carcinoma that is advanced or has spread.
- You are in generally good health (able to care for yourself and up and about).
- Your cancer can be measured on scans and has at least one tumor that can be tracked.
- You have already tried standard treatments like immunotherapy or targeted therapy, and they did not work or you couldn't take them.
- You have not had another cancer (other than kidney cancer) in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
Hear when a new Clear Cell Renal Cell Carcinoma (ccRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.